Ratings Photocure ASA

Equities

PHO

NO0010000045

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-26 am EDT			5-day change	1st Jan Change
55.4 ^NOK	+1.84%		+1.09%	-17.80%

Apr. 08	Photocure ASA Announces its Participation in the Congress, and Two Abstract Presentations at the 2024 European Association of Urology Congress in Paris, France	CI
Mar. 28	Photocure ASA Announces the Publication of the Study Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 59% by 2025.
Thanks to a sound financial situation, the firm has significant leeway for investment.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
PHOTOCURE ASA	-17.80%	136M	-
ELI LILLY AND COMPANY	+25.83%	661B	C+
NOVO NORDISK A/S	+27.00%	566B	B
JOHNSON & JOHNSON	-6.76%	352B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+3.00%	283B	C+
ASTRAZENECA PLC	+13.09%	231B	B+
NOVARTIS AG	+5.46%	200B	B-
ROCHE HOLDING AG	-9.61%	195B	A+
AMGEN INC.	-6.26%	145B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes